PolyPid Appoints New Oncology Advisory Board Member

Company is Scheduled to Conduct Pre-IND Meeting with the U.S. FDA Later This Month and Potentially Initiate Phase 1/2 Clinical Trial of OncoPLEX for Brain Tumors in 2022 PETAH TIKVA, Israel , Nov. 16, 2021 (GLOBE NEWSWIRE) — PolyPid Ltd. (Nasdaq: PYPD) (“PolyPid” or the “Company”), a phase 3